Washington Code 70.41.485 – Opioid overdose reversal medications — Distribution — Labeling — Liability
Current as of: 2023 | Check for updates
|
Other versions
(1) A hospital shall provide a person who presents to an emergency department with symptoms of an opioid overdose, opioid use disorder, or other adverse event related to opioid use with opioid overdose reversal medication upon discharge, unless the treating practitioner determines in their clinical and professional judgment that dispensing or distributing opioid overdose reversal medication is not appropriate or the practitioner has confirmed that the patient already has opioid overdose reversal medication. If the hospital dispenses or distributes opioid overdose reversal medication it must provide directions for use.
Terms Used In Washington Code 70.41.485
- Department: means the Washington state department of health. See Washington Code 70.41.020
- Discharge: means a patient's release from a hospital following the patient's admission to the hospital. See Washington Code 70.41.020
- Hospital: as used in this chapter does not include hotels, or similar places furnishing only food and lodging, or simply domiciliary care; nor does it include clinics, or physician's offices where patients are not regularly kept as bed patients for twenty-four hours or more; nor does it include nursing homes, as defined and which come within the scope of chapter 18. See Washington Code 70.41.020
- Person: means any individual, firm, partnership, corporation, company, association, or joint stock association, and the legal successor thereof. See Washington Code 70.41.020
(2) The opioid overdose reversal medication may be dispensed with technology used to dispense medications.
(3) A person who is provided opioid overdose reversal medication under this section must be provided information and resources about medication for opioid use disorder and harm reduction strategies and services which may be available, such as substance use disorder treatment services and substance use disorder peer counselors. This information should be available in all languages relevant to the communities that the hospital serves.
(4) The labeling requirements of RCW 69.41.050 and 18.64.246 do not apply to opioid overdose reversal medications dispensed or distributed in accordance with this section.
(5) Until the opioid overdose reversal medication bulk purchasing and distribution program established in RCW 70.14.170 is operational:
(a) If the patient is enrolled in a medical assistance program under chapter 74.09 RCW, the hospital must bill the patient’s medicaid benefit for the patient’s opioid overdose reversal medication utilizing the appropriate billing codes established by the health care authority. This billing must be separate from and in addition to the payment for the other services provided during the hospital visit.
(b) If the patient has available health insurance coverage other than medical assistance under chapter 74.09 RCW, the hospital must bill the patient’s health plan for the cost of the opioid overdose reversal medication.
(c) For patients who are not enrolled in medical assistance and do not have any other available insurance coverage, the hospital must bill the health care authority for the cost of the patient’s opioid overdose reversal medication.
(6) This section does not prohibit a hospital from dispensing opioid overdose reversal medication to a patient at no cost to the patient out of the hospital’s prepurchased supply.
(7) Nothing in this section prohibits or modifies a hospital’s ability or responsibility to bill a patient’s health insurance or to provide financial assistance as required by state or federal law.
(8) A hospital, its employees, and its practitioners are immune from suit in any action, civil or criminal, or from professional or other disciplinary action, for action or inaction in compliance with this section.
(9) For purposes of this section:
(a) “Opioid overdose reversal medication” has the meaning provided in RCW 69.41.095.
(b) “Practitioner” has the meaning provided in RCW 18.64.011.
[ 2021 c 273 § 3.]
NOTES:
Effective date—2021 c 273 §§ 2-4: See note following RCW 70.41.480.
Findings—Intent—2021 c 273: See note following RCW 70.41.480.